Irbesartan/Hydrochlorothiazide Teva

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

irbesartan, hydrochlorothiazide

Available from:

Teva B.V. 

ATC code:

C09DA04

INN (International Name):

irbesartan, hydrochlorothiazide

Therapeutic group:

Aġenti li jaġixxu fuq is-sistema renin-angiotensin

Therapeutic area:

Pressjoni għolja

Therapeutic indications:

Trattament ta 'ipertensjoni essenzjali. Din il-kombinazzjoni ta 'doża fissa hija indikata f'pazjenti adulti li l-pressjoni tad-demm tagħhom mhix ikkontrollata b'mod adegwat fuq irbesartan jew hydrochlorothiazide waħdu.

Product summary:

Revision: 22

Authorization status:

Awtorizzat

Authorization date:

2009-11-26

Patient Information leaflet

                                41
B. FULJETT TA’ TAGĦRIF
42
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
IRBESARTAN/HYDROCHLOROTHIAZIDE TEVA 150 MG/12.5 MG PILLOLI MIKSIJA
B’RITA
irbesartan / hydrochlorothiazide
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
•
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
•
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
•
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.
•
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
s-sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu Irbesartan/Hydrochlorothiazide Teva u għal xiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Irbesartan/Hydrochlorothiazide
Teva
3.
Kif għandek tieħu Irbesartan/Hydrochlorothiazide Teva
4.
Effetti sekondarji possibbli
5.
Kif taħżen Irbesartan/Hydrochlorothiazide Teva
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU IRBESARTAN/HYDROCHLOROTHIAZIDE TEVA U GĦAL XIEX JINTUŻA
Irbesartan/Hydrochlorothiazide Teva hu kombinazzjoni ta’ żewġ
sustanzi attivi, irbesartan u
hydrochlorothiazide. Irbesartan jappartjeni għall-grupp ta’
mediċini magħrufin bħala antagonisti tar-
riċetturi angiotensin-II. Angiotensin-II hija sustanza li tiġi
prodotta mill-ġisem stess li tingħaqad ma’
riċettaturi fil-vażi tad-demm u ġġalhom jissikkaw. Dan iwassal
għal żieda fil-pressjoni tad-demm.
Irbesartan ixekkel l-irbit ta’ angiotensin-II ma’ dawn
ir-riċettaturi, għalhekk il-vażi tad-demm
jirrilassaw u l-pressjoni tad-demm tonqos.
Hydrochlorothiazide hu wieħed minn gruppi ta’ mediċini (li
jissejħu dijuretiċi ta’ thiazide) li
jikkawżaw żieda fl-awrina u b’hekk tonqos il-pressjoni tad-demm.
Iż-żewġ sustanzi attivi f’Irbesartan/Hydroch
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg pilloli miksija
b’rita
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg pilloli miksija
b’rita
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg pilloli miksija
b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg pilloli miksija
b’rita
Kull pillola miksija b’rita fiha 150 mg ta’ irbesartan u 12.5 mg
ta’ hydrochlorothiazide.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg pilloli miksija
b’rita
Kull pillola miksija b’rita fiha 300 mg ta’ irbesartan u 12.5 mg
ta’ hydrochlorothiazide.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg pilloli miksija
b’rita
Kull pillola miksija b’rita fiha 300 mg ta’ irbesartan u 25 mg
ta’ hydrochlorothiazide.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita.
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg pilloli miksija
b’rita
Pillola miksija b’rita ta’ lewn roża ċara għal roża
f’għamla ta’ kapsula. Naħa waħda tal-pillola
għandha intaljata fuqha l-kodiċi "93". In-naħa l-oħra tal-pillola
hija intaljata bil-kodiċi "7238".
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg pilloli miksija
b’rita
Pillola tonda miksija b’rita ta’ lewn roża ċara għal roża.
Naħa waħda tal-pillola għandha intaljata
fuqha l-kodiċi "2" u n-naħa l-oħra ma fiha xejn.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg pilloli miksija
b’rita
Pillola tonda miksija b’rita ta’ lewn roża skura għal roża.
Naħa waħda tal-pillola għandha intaljata
fuqha l-kodiċi "3"u n-naħa l-oħra ma fiha xejn.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
It-trattament ta’ pressjoni għolja essenzjali.
Din il-kombinazzjoni ta’ doża fissa hi indikata għal pazjenti
adulti li għandhom pressjoni għolja li
mhix ikkontrollata sew b’irbesartan jew b’ hydrochlorothiazide
waħidhom (ara sezzjoni 5
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-06-2023
Public Assessment Report Public Assessment Report Bulgarian 10-11-2015
Patient Information leaflet Patient Information leaflet Spanish 16-06-2023
Public Assessment Report Public Assessment Report Spanish 10-11-2015
Patient Information leaflet Patient Information leaflet Czech 16-06-2023
Public Assessment Report Public Assessment Report Czech 10-11-2015
Patient Information leaflet Patient Information leaflet Danish 16-06-2023
Public Assessment Report Public Assessment Report Danish 10-11-2015
Patient Information leaflet Patient Information leaflet German 16-06-2023
Public Assessment Report Public Assessment Report German 10-11-2015
Patient Information leaflet Patient Information leaflet Estonian 16-06-2023
Public Assessment Report Public Assessment Report Estonian 10-11-2015
Patient Information leaflet Patient Information leaflet Greek 16-06-2023
Public Assessment Report Public Assessment Report Greek 10-11-2015
Patient Information leaflet Patient Information leaflet English 16-06-2023
Public Assessment Report Public Assessment Report English 10-11-2015
Patient Information leaflet Patient Information leaflet French 16-06-2023
Public Assessment Report Public Assessment Report French 10-11-2015
Patient Information leaflet Patient Information leaflet Italian 16-06-2023
Public Assessment Report Public Assessment Report Italian 10-11-2015
Patient Information leaflet Patient Information leaflet Latvian 16-06-2023
Public Assessment Report Public Assessment Report Latvian 10-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 16-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-06-2023
Public Assessment Report Public Assessment Report Lithuanian 10-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 16-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 16-06-2023
Public Assessment Report Public Assessment Report Hungarian 10-11-2015
Patient Information leaflet Patient Information leaflet Dutch 16-06-2023
Public Assessment Report Public Assessment Report Dutch 10-11-2015
Patient Information leaflet Patient Information leaflet Polish 16-06-2023
Public Assessment Report Public Assessment Report Polish 10-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 16-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 16-06-2023
Public Assessment Report Public Assessment Report Portuguese 10-11-2015
Patient Information leaflet Patient Information leaflet Romanian 16-06-2023
Public Assessment Report Public Assessment Report Romanian 10-11-2015
Patient Information leaflet Patient Information leaflet Slovak 16-06-2023
Public Assessment Report Public Assessment Report Slovak 10-11-2015
Patient Information leaflet Patient Information leaflet Slovenian 16-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 16-06-2023
Public Assessment Report Public Assessment Report Slovenian 10-11-2015
Patient Information leaflet Patient Information leaflet Finnish 16-06-2023
Public Assessment Report Public Assessment Report Finnish 10-11-2015
Patient Information leaflet Patient Information leaflet Swedish 16-06-2023
Public Assessment Report Public Assessment Report Swedish 10-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 16-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 16-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 16-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 16-06-2023
Patient Information leaflet Patient Information leaflet Croatian 16-06-2023
Public Assessment Report Public Assessment Report Croatian 10-11-2015

Search alerts related to this product